Clinical Trial

Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)

Study acronym: HEAL
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is an investigator-initiated Phase 1b clinical trial employing an open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of the investigational intervention and to determine the recommended dose for subsequent clinical studies.
Protocol Amendment History 2 changes
notable Trial sites expanded: 2 -> 10 locations 2026-08-08
critical Recruitment opened 2026-05-20
Trial Details
NCT Number NCT07513233
Lead Sponsor Capital Medical University
Conditions Acute Ischemic Stroke
Enrollment 92 participants
Start Date 2026-04-28
Primary Completion 2026-08-20 (estimated)
Study Completion 2026-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-07